Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Elevar Therapeutics
Pharma
FDA rejects Elevar, Hengrui's PD-1 combo
Elevar and Hengrui's camrelizumab continues the struggle China-made PD-1s have experienced with the FDA.
Angus Liu
May 17, 2024 10:16am
Hengrui, Elevar strike $600M marketing deal for liver cancer med
Oct 17, 2023 11:47am
Eisai, Astellas, GSK and more—Fierce Pharma Asia
Jul 21, 2023 8:15am